Given its highly variable clinical course, an unmet need for objective prognostic assessment in Multiple Sclerosis (MS) persists. In this work, we suggest that CSF kappa free light chains (KFLC) determination at first relapse may provide insight into future disease activity and disability worsening. We quantified KFLC by nephelometry in paired CSF/serum samples of 28 patients, collected within one month of first-ever MS relapse, and explored correlations with clinical data on disease activity, retrospectively registered across a median follow-up time of 79 months. We documented KFLC ratio (CSF-FKLC/Serum-KFLC) as an independent predictor of second relapse occurrence and disability worsening at follow-up, in this cohort.

中文翻译：

---

无κ轻链测定在首次多发性硬化复发中的预后价值

鉴于其高度可变的临床过程，对多发性硬化症 (MS) 客观预后评估的需求仍未得到满足。在这项工作中，我们建议在首次复发时测定 CSF κ游离轻链 (KFLC) 可以提供对未来疾病活动和残疾恶化的洞察。我们通过比浊法对 28 名患者的配对 CSF/血清样本中的 KFLC 进行量化，这些样本是在首次 MS 复发后一个月内收集的，并探索了与疾病活动性临床数据的相关性，在 79 个月的中位随访时间中进行了回顾性登记。我们记录了 KFLC 比率（CSF-FKLC/血清-KFLC）作为该队列中第二次复发和残疾恶化的独立预测因子。